Article information
Full text is only aviable in PDF
References
[1.]
A.D. Seidman.
Monotherapy options in the management of metastatic breast cancer.
Semin Oncol, 30 (2003), pp. 6-10
[2.]
Y. Lassere, P. Hoff.
Management of hand-foot syndrome in patients treated with capecitabine (Xeloda).
Eur J Oncol Nurs, 8 (2004), pp. 31-40
[3.]
W. Scheithauer, J. Blum.
Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine.
Oncology, 18 (2004), pp. 1161-1168
[4.]
L. Hueso, O. Sanmartín, E. Nagore, R. Botella-Estrada, C. Requena, B. Llombart, et al.
Eritema acral inducido por quimioterapia: estudio clínico e histopatológico de 44 casos.
Actas Dermosifiliogr, 99 (2008), pp. 281-290
[5.]
J.L. Yen-Revollo, R.M. Goldberg, H.L. McLeod.
Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines?.
Clin Cancer Res, 14 (2008), pp. 8-13
[6.]
K.A. Bell, A.G. Perna, S. Hsu.
Mucositis a treatment-limiting side effect in the use of capecitabine for the treatment of metastatic breast cancer.
J Am Acad Dermatol, 45 (2001), pp. 790-791
[7.]
G.Y. Chen, Y.H. Chen, N.M. Hsu, C.J. Tsao, W.C. Chen.
Onychomadesis and onycholisis associated with capecitabine.
Br J Dermatol, 145 (2001), pp. 521-522
[8.]
C. Vázquez-Bayo, A.L. Rodríguez-Bujaldón, R. Jiménez-Puya, M. Galán-Gutiérrez, J.C. Moreno-Giménez.
Hiperpigmentación secundaria a capecitabina.
Actas Dermosifiliogr, 98 (2007), pp. 491-493
[9.]
J.C. Pui, S. Meehan, T. Moskovits.
Capecitabine induced cutaneous hyperpigmentation: report of a case.
J Drug Dermatol, 1 (2002), pp. 202-205
[10.]
R. Tavares-Bello.
Capecitabine-induced hand-foot syndrome and cutaneous hyperpigmentation in an elderly vitiligo patient.
J Eur Acad Dermatol Venereol, 21 (2007), pp. 1434-1435
Copyright © 2009. Academia Española de Dermatología y Venereología and Elsevier España, S.L.
